Abstract: The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

Abstract: The present invention relates to bulk dry compositions comprising polyethylene glycol and an additive, such as a flavoring agent and/or sweetener, wherein the additive remains at a consistent concentration throughout the bulk composition. The invention also relates to processes for preparing the bulk dry compositions comprising polyethylene glycol.

Abstract: A method of preparing a modified-metal surface. The method includes preparing a solution of a phosphorous-based acid in a solvent; immersing a strip of the metal work piece into the solution of the phosphorous-based acid; immersing a strip of a reference metal into the solution of the phosphorous-based acid; supplying a voltage for a duration of time to prepare a phosphorous acid-modified metal work piece; removing the phosphorous acid-modified metal work piece; cleaning and drying the phosphorous acid-modified metal work piece; applying a chitosan solution to the surface in order to attach chitosan/modified chitosan to the phosphorous acid based modified surface; prepare the modified-metal surface; and cleaning and drying the modified-metal surface.

Abstract: The invention relates in particular to an injectable sclerosant drug foam comprising: (i) a matrix; (ii) at least one fluid; (iii) at least one sclerosant drug; (iv) a medical gas or medical gas mixture acceptable for intravenous use, (v) wherein said matrix has physical properties, which are comparable to denatured blood, wherein the denatured blood is obtainable from a fresh human venous whole blood sample of 1 ml volume, which is heated in a cylindrical polyethylene container with 3 mm inner diameter and 3.4 mm outer diameter for about 0.5 min. to about 10 min. at a temperature of about between 70° C. and 100° C. and/or (vii) said level of denaturation is defined by the change of red-colored hemoglobin to brown as an indicator, wherein Fe2+ is reduced to Fe3+ in the hemoglobin complex to a degree of at least 80%, preferably 90% and even more preferably 95%.

Abstract: A fluorine-containing ether compound of the present invention is represented by Formula (1). R1—CH2—R2—CH2—R3??(1) (In Formula (1), R1 is an organic end group having 3 or more carbon atoms which includes two or more polar groups with each polar group being bonded to different carbon atoms and the carbon atoms to which the polar groups are bonded being bonded to each other via a linking group including the carbon atoms which are not bonded to the polar groups, R2 includes a perfluoropolyether chain represented by Formula (3), and R3 is a hydroxyl group or R1) —(CF2)y?1—O—((CF2)yO)z—(CF2)y?1—??(3) (In Formula (3), y represents an integer of 2 to 4, and z represents an integer of 1 to 30).

Abstract: Disclosed is an antimicrobial composition that includes a) one or more C3 to C5 alkane dioles-1,3, b) one or more aromatic alcohols and c) one or more C8 to C14 alkanols. A preferred component a) is propane diol-1,3. Preferred components b) are phenoxyethanol and phenethyl alcohol. A preferred component c) is undecanol-1. Optionally, an antioxidant c) is present, which is preferably Vitamin E. In a preferred embodiment the composition is a concentrate and is suitable for the antimicrobial finishing of dermatological, cosmetic and pharmaceutical products.

Abstract: The present invention relates to the cosmetic treatment of greasy skin and/or skin that tends to be greasy with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, as an active.

Abstract: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.

Abstract: The invention relates to a microbicidal composition which comprises a mixture of at least two components, the first component being 2-methyl-3-isothiazolone (MIT) and the second component being at least one active compound selected from the following groups of active compounds: a) compound having activated methylol groups b) quats or polyquats c) carbamates d) organic acids e) aromatic alcohols.

Abstract: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

Abstract: Embodiments described herein provide a dialysate comprising a polyglycerol. The polyglycerol may be of a molecular weight between about 0.15 kDa and about 60 kDa. Also provided herein is the use of the dialysate as a diffusion agent and as an osmotic agent.

Abstract: Disclosed are antimicrobial compositions, and methods for killing, inhibiting, or preventing the growth of microbes, using trimethylene glycol oligomers or dimers. The trimethylene glycol oligomers and dimers have the formula R(CH2CH2CH2—O—CH2CH2CH2)nR1 where R and R1 are hydroxyl, amine, or ester functionalitiess, and n is 2 or higher. The antimicrobial compositions are useful in personal care and cosmetic compositions.

Abstract: One larger [1] and one smaller tube [2], forming a functional unit with the smaller tube [2] positioned within the larger tube [1], both tubes are relocatable and demountable, both tubes with an aperture [3 and 4] at both ends, at least one aperture [5] being provided in the wall of the outer tube located at a distance of about between 1 mm and 10 cm from the tip [6], or several apertures positioned in a segment of 1-250 mm from the tip, wherein the diameter of the single aperture is between 70% and 120% of the inner diameter of the outer tube [1], or in case of several apertures, for each aperture 30-60% of the inner diameter of the outer tube, wherein the outer diameter of the inner tube is between 0.6 mm and 2.0 mm (F2 to F6), the outer diameter of the outer tube is between 1.3 mm and 3.6 mm (F4 to F11), and the distance between the outer wall of the inner tube and the inner wall of the outer tube is between 0.1 mm to 3.0 mm.

Abstract: Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.

Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.

Abstract: The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

Abstract: Use of pegylated alcohols for the treatment of actinic keratosis.

Abstract: The present invention relates to novel glycerin ether ethoxylate solfactant compounds, compositions employing the same, and methods of using these compounds. Beneficially the compounds have efficacy as both solvents and surfactants with low foam and low viscosity. The compounds of the present invention can be used as antimicrobials and/or sanitizing agents in various formulations. The compounds of the present invention are also suitable for use as solvents and/or hydrotropes.

Abstract: The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.

Abstract: A composition for treating dandruff is provided. The composition includes glycerol with a concentration of not larger than 10 wt %, a second, low molecular weight polyol with a concentration of not larger than 10 wt %, and a saline solution. The composition is free of chemical surfactants, antiseptics, or foaming agents and the like, which may cause allergic or hypersensitive conditions, and has the advantages of simple constituents, low cost, and effective outcomes on the treatment of dandruff. Long-term application of the composition on the scalp is therefore suggested.

Abstract: The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or said matrix is impregnated with said polymeric material, or both.

Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, antioxidants, and enzyme inhibitors.

Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.

Abstract: The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate.

Abstract: The invention is directed to an edible solid composition having laxative properties. The composition has a smooth mouth feel, in non-gritty and has a pleasant taste. It is prepared by melt-combining together the ingredients including a bulking agent and laxative as well as an optional flavor agent and electrolyte. The melt is a dispersion containing a substantially homogeneous combination of ingredients. The melt is cooled to form an amorphous solid dispersion or solution of the ingredients. The ingredients are mutually compatible so that upon cooling they do not separately crystallize to form a gritty mouth feel product.

Abstract: The present invention relates to shape memory polymers (SMP) and especially to shape memory polymer containing a water soluble non-reactive plasticiser and to uses thereof.

Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Abstract: Methods for treating arthropods comprising depositing at least one drop of a liquid formulation containing at least one surfactant on a solid surface of an arthropod at a contact angle sufficient to cause rapid and enhanced knockdown (KD) of the arthropod. The contact angle comprises an angle formed between a resting drop of the liquid formulation and the solid surface on which the drop rests measured, after a period of about 80 milliseconds (ms) or more from the time that a drop of the liquid formulation is deposited on the solid surface, at a contact point between a tangent line drawn on a liquid/vapor interface surface of the resting drop in contact with the solid surface and a tangent to the solid surface on which the drop rests.

Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R1, R2, R3, R4, R5 and R6 is hydroxyl and the other of R1, R2, R3, R4, R5 and R6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, ammo, lmmo, azido, thiol, thioalkyl, thioaryl, mtro, cyano, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carbonyl, carbamoyl or carbamide, or pharmaceutically acceptable salts thereof. Said derivatives and compositions comprising the same are useful in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence.

Abstract: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41% of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.

Abstract: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

Abstract: This invention relates to a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents that leave undesirable deposits or a sticky after-feel and that has a final viscosity less than 4,000 cps. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a fluorosurfactant of at least 0.001% by weight to prepare a foamable composition or from 0-2.0% to prepare a gel-like composition of a final viscosity less than 4,000 cps, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition or a gel-like composition with a viscosity less than 4,000 cps), and the balance being purified water.

Abstract: A concentrated poly(ethylene glycol) solution that has good stability for extended storage is provided for use as a laxative. The concentrated solution comprises water, sodium benzoate, poly(ethylene glycol), and enough acid to yield a solution having a pH at 25° C. in the range 3.0-5.0. It is prepared and packaged to minimize the accumulation of degradation products.

Abstract: The present invention teaches a surfactant blend composition of at least one nonionic alkoxylate and at least one sugar-based surfactant, and its use as an adjuvant for pesticides. The pesticidal composition employing the surfactant blend composition of the invention realizes an efficacy that is unexpectedly superior to similar pesticidal compositions which employ only the individual surfactant components. The composition of the present invention is useful as a tank side additive, or as a component in herbicidal formulations. In addition the compositions of the present invention are useful as adjuvants for other pesticides, such as, fungicides, insecticides, plant growth regulators, acaracides and the like.

Abstract: In accordance with the present invention, methods are provided for the prevention and/or treatment of enteropathogenic bacterial infection in the gastrointestinal tract of a subject, and the diarrhea associated with the infection, by administration to the subject of a low molecular weight polyethylene glycol, as well concurrent administration with other antibiotic and antidiarrheal agents. Methods for reduction or suppression of inflammation, and inhibition of ?1-integrin expression in the gastrointestinal mucosa are also provided. Also described is a kit suitable for use with the methods disclosed.

Abstract: Compositions comprising polyethylene glycol (PEG) are disclosed for the prophylaxis and/or treatment of head and neck squamous cell carcinomas (HNSCC). Methods for the prophylaxis and/or treatment of HNSCC comprising administering an effective amount of PEG are also disclosed. Also disclosed are methods and compositions for suppressing the surface expression of EGFR using PEG.

Abstract: Disclosed herein are foamable gritty foam compositions that can suspend particulate mechanical scrubbers with particles sized from about 100 microns to about 800 microns that is capable of being foamed through a non-aerosol, or unpressurized pump dispenser.

Abstract: Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment, at least one analyte may be collected and analyzed from the solubilized tissue.

Abstract: Provided are new functionalized surfactants and methods of their preparation and use. The surfactants are compounds of formula I: wherein R1, R2, and R3 are as defined herein.

Abstract: Method for reducing the formaldehyde emission of a composition containing a formal by adding urea, urea derivatives, amino acids, guanidine or guanidine derivatives.

Abstract: The present invention provides drug-free adaptable aggregate compositions, typically having a form of bilayer vesicles suspended in a polar, optionally thickened, fluid comprising different pharmaceutically acceptable excipients for use in or on a mammal for any medical indication, specifically for non-invasive treatment of local inflammation and the associated pain, in particular for use on the skin and underlying tissues, including muscles and/or superficial joints. Accompanying guidelines for selecting components to thereby optimizing the formulations are also provided.

Abstract: The invention relates to a composition comprising an oil-soluble high carbon polar modified polymer and a hyperbranched polyol.

Abstract: The present invention relates to novel glycerin ether ethoxylate solfactant compounds, compositions employing the same, and methods of using these compounds. Beneficially the compounds have efficacy as both solvents and surfactants with low foam and low viscosity. The compounds of the present invention can be used as antimicrobials and/or sanitizing agents in various formulations. The compounds of the present invention are also suitable for use as solvents and/or hydrotropes.

Abstract: In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.

Abstract: The present disclosure is directed to a radiation curable coating composition comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial coating layer formed from the coating composition comprising low molecular weight polytrimethylene ether glycol. The coating compositions can be used as interior and exterior top coats, basecoats, primers, primer surfacers and primer fillers. The disclosure is particularly directed to a coating composition comprising components derived from renewable resources.

Abstract: An edible, gel composition of a PEG and a gel forming agent wherein the composition is prepared by mixing together the PEG with gel forming agent to form the edible gel composition, and the edible gel composition has laxative properties.

Abstract: An edible, solid composition comprising a laxative and one or more bulking agents in aqueous media wherein the laxative is polyethylene glycol and the composition is prepared by dissolving the polyethylene glycol in aqueous media together with one or more bulking agents and subjecting the mixture to heat up to at least about 100° C.